Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (163313)	10/4/2020 9:59:15 AM
From: arun gera	1 Recommendation Recommended By marcher Respond to of 218697

Interestingly, Trump used to have stocks of both Gilead and Regeneron in 2017 (he had very few Pharma stocks in all). usatoday.com President Donald Trump previously reported he earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., the manufacturers of two of the medicines he's taken as part of his COVID-19 treatment plan. According to a 2017 financial disclosure form filed with the U.S. Office of Government Ethics in June 2017, Trump had a capital gain of $50,001 to $100,000 for Regeneron Pharmaceuticals and $100,001 to $1 million for Gilead Sciences Inc. The form notes the information was of April 15, 2017. Trump’s subsequent disclosure forms, including his 2020 form signed July 31, did not list Regeneron or Gilead. Is he really sick or he is personally dictating the medicines he is taking? And getting the spelling of Regeneron wrong in the official press release. Nobody dared to correct the spelling. twitter.com -Arun

To: TobagoJack who wrote (163313)	10/4/2020 10:11:32 AM
From: arun gera	Respond to of 218697

<THESE DRUGS HAVE NEVER BEEN STUDIED FOR THEIR COMBINED EFFECTS ON A PATIENT. AND NOW THAT PATIENT…THE FIRST PATIENT RECEIVING THEM…IS THE PRESIDENT OF THE UNITED STATES.> Maybe not the first... Monolclonal antibodies + remdesivir are being tested in Phase 3 clinical trials. nih.gov I confess I have not investigated the real difference between monoclonal and polyclonal antibodies. -Arun

To: TobagoJack who wrote (163313)	10/4/2020 10:14:17 AM
From: arun gera	1 Recommendation Recommended By marcher Respond to of 218697

<Why is Trump being given experimental drugs and not the known safe HCQ cure?> Because Trump has known for some time that HCQ does not work. Just like he had early information in February that Covid was very dangerous. You can see that he stopped believing in HCQ when he suggested injecting with disinfectant, shining heat and light. However, Trump supporters continue to obsess on HCQ, while practicing doctors are working with protocols that are showing more promise. -Arun

To: TobagoJack who wrote (163313)	10/4/2020 12:07:05 PM
From: arun gera	Read Replies (3) \| Respond to of 218697

Is he working or hardly working at Walter Read. Signing blank papers with a sharpie. independent.co.uk Now trending on twitter #staged twitter.com

To: TobagoJack who wrote (163313)	10/4/2020 1:10:02 PM
From: arun gera	Read Replies (2) \| Respond to of 218697

And now the last resort drug dexamethasone has been added. They are throwing everything into his treatment... statnews.com They might as well throw in HCQ too. The mortality rate is about 25% for those on oxygen support, unless the drug combo brings it down further. But Trump's doctor predicts, he will be well by Monday. That will really be a miracle! nejm.org METHODSIn this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the preliminary results of this comparison. RESULTSA total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.91 to 1.55). CONCLUSIONSIn patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936. opens in new tab; ISRCTN number, 50189673. opens in new tab.) -Arun

To: TobagoJack who wrote (163313)	10/5/2020 2:45:58 PM
From: THE ANT	Respond to of 218697

Silly Meanwhile SRPT to the rescue?(Only for China) Its dying in rest of the world) news-medical.net

To: TobagoJack who wrote (163313)	10/5/2020 3:04:12 PM
From: THE ANT	Respond to of 218697

Should of used Ivermictan

To: TobagoJack who wrote (163313)	10/6/2020 10:06:05 AM
From: THE ANT	1 Recommendation Recommended By elmatador Read Replies (1) \| Respond to of 218697

Sorry for short answer yesterday, wife was in surgery. Monoclonal ABTS and steroids are very low risk, as are likely antivirals High risk is vaccines Brazil looking great record industrial production, large trade surplus, virus gone within 2 months, More important the politicians and judiciary have decided to forgive past corruption sins and put the petal to the metal in reforming Brazil. Political pedal to the metal in Brazil is still slow